The HB22.7-vcMMAE Antibody-Drug Conjugate Has Efficacy Against Non-Hodgkin Lymphoma Xenografts with Minimal Systemic Toxicity

• Published in: Cancer immunology, immunotherapy : CII Vol. 65; no. 10; pp. 1169 - 1175
• Main Authors: Abuhay, Mastewal, Kato, Jason, Tuscano, Emily, Barisone, Gustavo A., O’Donnell, Robert T., Tuscano, Joseph M.
• Format: Journal Article
• Language: English
• Published: 09.08.2016
• ISSN: 0340-7004; 1432-0851
• DOI: 10.1007/s00262-016-1873-y

In this study, the HB22.7 anti-CD22 mAb, was used for specific, targeted delivery of the potent anti-cancer agent, monomethyl auristatin E (MMAE) to non-Hodgkin lymphoma (NHL). MMAE was covalently coupled to HB22.7 through a valine-citrulline peptide linker (vc). Maleimide-functionalized vcMMAE (mal-vcMMAE) was reacted with thiols of the partially reduced mAb. Approximately 4 molecules of MMAE were conjugated to HB22.7 as determined by residual thiol measurement and hydrophobic interaction chromatography-HPLC (HIC-HPLC). HB22.7-vcMMAE antibody drug conjugate (ADC) retained its binding to Ramos NHL cells and also exhibited potent and specific in vitro cytotoxicity on a panel of B cell NHL cell lines with IC 50 s of 20 - 284 ng/ml. HB22.7-vcMMAE also showed potent efficacy in vivo against established NHL xenografts using the DoHH2 and Granta 519 cell lines. One dose of the ADC induced complete and persistent response in all DoHH2 xenografts and 90% of Granta xenografts. Minimal toxicity was observed. In summary, HB22.7-vcMMAE is an effective ADC that should be evaluated for clinical translation.